Form 4: Eliem Therapeutics EVP Valerie Morisset Reports Stock Option Exercise and Sale

Valerie Morisset, EVP, R&D and CSO of Eliem Therapeutics, exercised stock options and sold shares on July 1st and 3rd, 2024.

Summary

• Valerie Morisset, the EVP, R&D and CSO of Eliem Therapeutics, Inc. (ELYM), filed a Form 4 detailing changes in beneficial ownership.
• On July 1, 2024, Morisset exercised a stock option for 7,649 shares of common stock at a price of $0.0002 per share.
• Following the exercise, Morisset sold 50,000 shares of common stock on July 3, 2024, at a price of $6.76 per share.
• After these transactions, Morisset directly owns 462,956 shares of Eliem Therapeutics common stock and 10,198 stock options.

Sentiment

Score: 5

Explanation: Form 4 filings are neutral in sentiment as they simply report transactions. The sale of shares could be interpreted in various ways, but without additional context, it's difficult to assign a strong positive or negative sentiment.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like executives and directors, trade their company's stock. These filings provide transparency into insider transactions and can be monitored by investors for insights into management's perspective on the company's value and future prospects.

Stakeholder Impact

• Shareholders may interpret the stock sale as a signal, though further context would be needed to determine the significance.

Key Dates